

Pure red cell aplasia (PRCA)

Condition for which IVIg use is in exceptional circumstances only

Specific Conditions

- Pure red cell aplasia

Level of Evidence

Nil (Category 4b)

PRCA is a rare syndrome of severe anaemia, reticulocytopenia and a selective deficiency of erythroid progenitors. Intravenous immunoglobulin (IVIg) should be considered as first-line therapy for viral PRCA associated with parvovirus B19 in immunocompromised patients. IVIg is a reasonable option for patients with immunological PRCA who have failed other therapies (e.g. prednisone or cyclosporine).

Refer to the current product information sheet for further information.

The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.

Bibliography

Anderson, D, Ali, K, Blanchette, V, et al 2007, 'Guidelines on the use of intravenous immune globulin for hematologic conditions', *Transfusion Medicine Reviews*, vol. 21, no. 2, suppl. 1, pp. S9–56.

Generated on: 31 March 2019